Hypoxia-inducible factor-1 (HIF-1) plays important roles in regulating radiosensitivity, making it a potentially promising target for tumour radiosensitisation. Here, we discuss the rationale for, and the potential pitfalls of, combining HIF-1 blockade with radiotherapy. In doing so, we describe clinical scenarios in which HIF-1 inhibition might optimise tumour radiosensitivity.
展开▼